We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MediWound (MDWD) Moves 6.1% Higher: Will This Strength Last?
Read MoreHide Full Article
MediWound (MDWD - Free Report) shares soared 6.1% in the last trading session to close at $14.2. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 1.8% gain over the past four weeks.
The stock price gain likely reflects MediWound’s broader optimism about the commercial prospects of NexoBrid, its marketed therapy for enzymatic eschar removal in patients with deep partial- and full-thickness thermal burns. The product has demonstrated solid commercial momentum, supported by growing hospital adoption and record quarterly revenue and unit sales in the second quarter. Investors may also be encouraged by progress with EscharEx, an investigational therapy for debridement of chronic wounds, which is also advancing through a late-stage study for venous leg ulcers.
This developer of treatments for burns and hard-to-heal wounds is expected to post quarterly loss of $0.66 per share in its upcoming report, which represents a year-over-year change of -175%. Revenues are expected to be $7.63 million, up 40.4% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For MediWound, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on MDWD going forward to see if this recent jump can turn into more strength down the road.
MediWound is part of the Zacks Medical - Drugs industry. Korro Bio, Inc. (KRRO - Free Report) , another stock in the same industry, closed the last trading session 4.8% higher at $16.62. KRRO has returned 62.5% in the past month.
Korro Bio, Inc.'s consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$1.14. Compared to the company's year-ago EPS, this represents a change of +40.6%. Korro Bio, Inc. currently boasts a Zacks Rank of #3 (Hold).
View the Zacks #1 Rank List
Image: Bigstock
MediWound (MDWD) Moves 6.1% Higher: Will This Strength Last?
MediWound (MDWD - Free Report) shares soared 6.1% in the last trading session to close at $14.2. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 1.8% gain over the past four weeks.
The stock price gain likely reflects MediWound’s broader optimism about the commercial prospects of NexoBrid, its marketed therapy for enzymatic eschar removal in patients with deep partial- and full-thickness thermal burns. The product has demonstrated solid commercial momentum, supported by growing hospital adoption and record quarterly revenue and unit sales in the second quarter. Investors may also be encouraged by progress with EscharEx, an investigational therapy for debridement of chronic wounds, which is also advancing through a late-stage study for venous leg ulcers.
This developer of treatments for burns and hard-to-heal wounds is expected to post quarterly loss of $0.66 per share in its upcoming report, which represents a year-over-year change of -175%. Revenues are expected to be $7.63 million, up 40.4% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For MediWound, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on MDWD going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
MediWound is part of the Zacks Medical - Drugs industry. Korro Bio, Inc. (KRRO - Free Report) , another stock in the same industry, closed the last trading session 4.8% higher at $16.62. KRRO has returned 62.5% in the past month.
Korro Bio, Inc.'s consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$1.14. Compared to the company's year-ago EPS, this represents a change of +40.6%. Korro Bio, Inc. currently boasts a Zacks Rank of #3 (Hold).